• LAST PRICE
    0.0001
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 0.0001
  • Day Range
    ---
  • 52 Week Range
    Low 0.0001
    High 0.0035
  • Volume
    ---

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.0001
TimeVolumeTHER
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTHER
Theralink Technologies Inc
615.2K
0.0x
---
United StatesCMRA
Comera Life Sciences Holdings Inc
768.4K
-0.1x
---
United StatesPKBO
Peak Bio Inc
194.6K
0.0x
---
United StatesAVXT
AVAX Technologies Inc
140.0
0.0x
---
United StatesVPRO
Viropro Inc
1.2K
0.0x
---
United StatesCXBS
Corix Bioscience Inc
20.0
0.0x
---
As of 2024-06-21

Company Information

Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.

Contact Information

Headquarters
8000 INNOVATION PARK, DR, BATON ROUGEBATON ROUGE, LA, United States 70820
Phone
225-578-7555
Fax
---

Executives

Chairman of the Board
Jeffrey Busch
President, Chief Executive Officer, Chief Operating Officer
Faith Zaslavsky
Chief Financial Officer, Director
Andrew Kucharchuk
Chief Medical Officer, Director
Michael Ruxin
Independent Director
Yvonne Fors

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$615.2K
Revenue (TTM)
$635.5K
Shares Outstanding
6.2B
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$0.00
Book Value
$-0.01
P/E Ratio
0.0x
Price/Sales (TTM)
1.0
Price/Cash Flow (TTM)
---
Operating Margin
-1,251.16%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.